Gingko Biloba efficacy in treatment of drug-induced parkinsonism

Assessment of Gingko Biloba efficacy in treatment of drug-induced parkinsonism:; A randomized, double-blind, placebo-controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200708048060N1

Enrollment

102

Registered

2022-06-06

Start date

2022-06-20

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug-induced parkinsonism. Other drug-induced secondary parkinsonism

Interventions

Intervention 1: Intervention group: Intervention group: Ginkgo biloba tablets - 40 mg every 8 hours 2 tablets (daily dose 240 mg) - for 3 months - drug manufacture: tolid darou. Intervention 2: Contro

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All psychiatric patients with the symptoms of drug induced parkinsonism, who have been given neurological counseling and Parkinson's drug-induced event has been confirmed based on clinical judgments and other findings among them Age over 18 years

Exclusion criteria

Exclusion criteria: Thrombocytopenia Coagulopathy Kidney failure Liver failure GI bleeding history Consumption of warfarin, high dose NSAIDs or NSAIDS with SSRIs and CCBs.

Design outcomes

Primary

Measure	Time frame
Improving the quality of life of patients. Timepoint: before intervention and 1 and 3 months after intervention. Method of measurement: PDQ-39 questionnaire.;Improving the severity of drug induced parkinsonism symptoms in patients. Timepoint: before intervention and 1 and 3 months after intervention. Method of measurement: Unified Parkinson's Disease Rating Scale ( UPDRS ) questionnaire Simpson-Angus Extrapyramidal Side Effects Scale (SAS ) questionnaire.;Improving the cognitive function in patients. Timepoint: before intervention and 1 and 3 months after intervention. Method of measurement: MoCA (Montreal Cognitive Assessment) questionnaire.	—

Measure

Time frame

Improving the quality of life of patients. Timepoint: before intervention and 1 and 3 months after intervention. Method of measurement: PDQ-39 questionnaire.;Improving the severity of drug induced parkinsonism symptoms in patients. Timepoint: before intervention and 1 and 3 months after intervention. Method of measurement: Unified Parkinson's Disease Rating Scale ( UPDRS ) questionnaire Simpson-Angus Extrapyramidal Side Effects Scale (SAS ) questionnaire.;Improving the cognitive function in patients. Timepoint: before intervention and 1 and 3 months after intervention. Method of measurement: MoCA (Montreal Cognitive Assessment) questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiayesh Mohebbi

Tehran University of Medical Sciences

niayesh_mohebbi@yahoo.com+98 21 6695 4709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026